FREQUENCY OF ISOCITRATE DEHYDROGENASE (IDH) MUTATIONS IN PATIENTS WITH GLIOMAS PRESENTING TO NEUROSURGERY DEPARTMENT HMC HOSPITAL PESHAWAR
DOI:
https://doi.org/10.48047/HM.10.2.2024.1696-1702Keywords:
Glioma, IDH mutations, Astrocytoma, Oligodendroglioma, Brain tumor, Glioma gradingAbstract
Introduction: Gliomas are common and aggressive brain tumors, with their prognosis largely influenced by genetic alterations, including mutations in the isocitrate dehydrogenase (IDH) gene. IDH mutations, particularly prevalent in lower-grade gliomas, are associated with better survival rates and have become key biomarkers for diagnosis and treatment strategies. This study aimed to determine the frequency of IDH mutations in glioma patients at Hayatabad Medical Complex (HMC) in Peshawar.
Materials and methods: A descriptive, cross-sectional study was conducted on 127 glioma patients in the Neurosurgery Department at HMC. Non-probability consecutive sampling was used. Patients aged 12-60 years, diagnosed with gliomas, and undergoing surgery were included. Exclusion criteria were prior brain surgery, preoperative radiotherapy or chemotherapy, and refusal of DNA sequencing consent. Tumor tissue was analyzed for IDH mutations using polymerase chain reaction (PCR). Data were analyzed using SPSS, with a chi-square test used to determine statistical significance (p ≤ 0.05).
Results: Of the 127 patients, the mean age was 41.7 years. Glioma types included Astrocytoma (46.5%), Oligodendroglioma (29%), and Ependymoma (24.5%). IDH mutations were present in 57% of cases. IDH mutations were significantly more common in Glioma Grades 2 and 4. The age distribution and IDH mutation status showed statistically significant differences across the glioma grades (p < 0.05).
Conclusion: IDH mutations were found in over half of the glioma cases, predominantly in lower and higher tumor grades.
Downloads
References
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. [1]The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109.
Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee [2]WK, et al. The 2016 World Health Organization classification of tumours of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803-20.
Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, et al. IMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135(4):639-42.
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, Von Deimling A. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta neuropathologica. 2018 Nov;136:805-10.
Diamandis P, Aldape K. World Health Organization 2016 Classification of Central Nervous System Tumors. Neurologic clinics. 2018 Aug 1;36(3):439-47.
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. The American journal of pathology. 2009 Apr 1;174(4):1149-53.
Chen N, Yu T, Gong J, Nie L, Chen X, Zhang M, Xu M, Tan J, Su Z, Zhong J, Zhou Q. IDH1/2 gene hotspot mutations in central nervous system tumours: analysis of 922 Chinese patients. Pathology. 2016 Dec 1;48(7):675-83.
Mellai M, Piazzi A, Caldera V, Monzeglio O, Cassoni P, Valente G, Schiffer D. IDH1 and IDH2 mutations, immunohistochemistry, and associations in a series of brain tumors. Journal of neuro-oncology. 2011 Nov;105:345-57.
Rasmussen BK, Hansen S, Laursen RJ, Kosteljanetz M, Schultz H, Nørgård BM, Guldberg R, Gradel KO. Epidemiology of glioma: Clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the Danish Neuro-Oncology Registry. Journal of Neuro-oncology. 2017 Dec;135:571-9.
Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta neuropathologica. 2008 Dec;116:597-602.
Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, Von Deimling A. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta neuropathologica. 2011 Feb;121:241-22.
Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S. Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age. Neuro-oncology. 2013 Apr 1;15(4):423-32.
Hu X, Miao W, Zou Y, Zhang W, Zhang Y, Liu H. Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncology letters. 2013 Jul 1;6(1):130-4.
Popova SN, Bergqvist M, Dimberg A, Edqvist PH, Ekman S, Hesselager G, Ponten F, Smits A, Sooman L, Alafuzoff I. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology. 2014 Feb;64(3):365-79.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Muhammad Ibrahim Afridi, Sonia Umar Afridi, Sohaib Ali, Tauseef Ullah (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
